In re Bristol-Myers Squibb Company Securities Litigation
|Court:||United States District Court for the Southern District of New York|
|Class Period:||01/27/2015 - 10/09/2016|
|Case Contacts:||Lauren McMillen Ormsbee, Jesse L. Jensen|
This is a securities fraud class action filed on behalf of a class of all persons and entities who purchased or otherwise acquired common shares of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) between January 27, 2015 and October 9, 2016, inclusive (the “Class Period”).
Bristol-Myers is a global biopharmaceutical company that develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. This action arises from allegations that Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, it is alleged that Bristol-Myers failed to disclose material information concerning the Company’s CheckMate-026 study, which was investigating the use of Opdivo (nivolumab) monotherapy as first-line therapy in patients with advanced non-small cell lung cancer (“NSCLC”).
As alleged in the action, the Defendants failed to inform investors that Bristol-Myers’ CheckMate-026 trial was more likely to fail than Defendants were representing. When the Company announced on August 5, 2016 that its CheckMate-026 trial had failed, and that Opdivo it did not meet its primary endpoint of progression-free survival, Defendants’ false and misleading statements and omissions began to be revealed and the Company’s stock price fell 16% that same day, and continued to fall another 4.7% on the next trading day, closing at $60.30 per share on August 8, 2016.
The Court appointed Arkansas Public Employees’ Retirement Services and Louisiana Sheriffs as Co-Lead Plaintiffs on May 16, 2018.
Plaintiffs filed a Consolidated Amended Complaint on July 16, 2018. On September 10, 2018, Defendants moved to dismiss the Complaint.
On September 30, 2019, the Court granted Defendants’ motion to dismiss, but gave Plaintiffs leave to file an amended complaint within 30 days. On October 29, 2019, we timely filed a Second Amended Complaint, which added additional allegations based on information provided by former Bristol-Myers employees as well as an expert in oncology. After asking for an extension of the briefing schedule, Defendants filed their motion to dismiss on December 13, 2019. On January 27, 2020, we will file our opposition brief, and Defendants’ reply brief is due on February 28, 2020.
Other Cases of Interest
McDermott International, Inc.
Southern District of Texas Lauren McMillen Ormsbee, James M. Fee
Northern District of California Lauren McMillen Ormsbee, Alexander T. Payne
HealthSouth Corporation Inc.
Northern District of Alabama, Southern Division Max W. Berger, Salvatore J. Graziano, Lauren McMillen Ormsbee
Southern District of New York Lauren McMillen Ormsbee, Michael Mathai
Perrigo Company plc
District of New Jersey James A. Harrod, Jesse L. Jensen, R. Ryan Dykhouse
Macquarie Infrastructure Corporation
Southern District of New York Salvatore J. Graziano, Lauren McMillen Ormsbee, Jesse L. Jensen, James M. Fee
GT Advanced Technologies Inc.
District of New Hampshire John C. Browne, Lauren McMillen Ormsbee
Allergan, Inc. (Drug Pricing)
District of New Jersey John C. Browne, Lauren McMillen Ormsbee
Cognizant Technology Solutions
District of New Jersey John Rizio-Hamilton, Abe Alexander, Jesse L. Jensen